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Background: In successful reproduction, endocrine and immune systems closely interact. We here attempt to
further elucidate the relationship between androgen levels, systemic activation of the immune system and
reproductive success in infertile women, utilizing 2 distinct infertile patient cohorts.
Methods: In Group 1, we investigated 322 women (ages 38.6 +/− 5.4 years) at initial presentation; in Group 2 125
women undergoing in vitro fertilization (169 IVF cycles, ages 38.9 +/− 5.5 years). In Group 1, we assessed androgens
and an immune panel, previously demonstrated to discriminate between activated quiescent immune systems; in
Group 2, utilizing the same immune panel, we investigated whether immune system activation relates to embryo
quality in IVF cycles.
Results: No individual immune test within the immune panel was associated with androgen levels. The total/free
testosterone ratio (TT/FT) was, however, significantly associated with presence of gammopathies (in IgG, IgM, IgA,
IgE; P = 0.026). Surprisingly, immune system activation was associated with significantly improved embryo quality
(P = 0.008), a finding persistent after adjustment for age and repeat IVF cycles (P = 0.006).
Conclusions: Association of immune system activation with improved embryo quality concurs with previously
reported immune activation in association with normal functional ovarian reserve (FOR) and normal androgen
levels, while, counter intuitively, hypoandrogenism and low FOR are associated with lack of immune system
activation. Mild immune system activation, therefore, likely appears essential for establishment of pregnancy,
and may be regulated by androgens.
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Since the implanting embryo is a paternal semi-allograft,
successful implantation in the maternal uterus is akin to
allogeneic transplantation of a “mini-multiorgan transplant”
to the mother. Establishment of pregnancy is, therefore, an
immunologically mediated process.
To tolerate the transplant, the mother’s immune system
has to “reprogram” itself from rejection to tolerance. How
this happens is only incompletely understood [1], but
evidence suggests that a normal immune system does* Correspondence: ngleicher@thechr.com
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unless otherwise stated.this well, while excessively activated immune systems
(severely hyper allergenic women or women with inflam-
mation and/or active autoimmunity), do not. Inadequate
maternal tolerance then leads to allogeneic maternal
immune responses against the implanting fetus and failed
implantation and/or pregnancy loss [2].
Since even healthy individuals frequently, demonstrate
laboratory evidence suggestive of immune system hyper-
activity, normal quiescence versus activation is not well
defined. For example, autoimmune abnormalities are
frequently found in association with allergies [3] or even
in normal patient populations [4,5], yet, even if just
sub-clinical, have been associated with reproductive
problems, including infertility, miscarriage risk [6,7] andral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Table 1 Baseline characteristics of Groups 1 and 2*
Group 1 Group 2
(n = 322) (n = 125)
Age (years) 38.6 ± 5.4 38.9 ± 5.4
BMI** (kg/m2) 24.0 ± 4.9 24.1 ± 4.6
DHEA (ng/dL) 469.2 ± 289.8 467.9 ± 308.9
DHEAS (μg/dL) 253.5 ± 189.0 371.6 ± 233.4
Total testosterone (ng/dL) 26.0 ± 13.7 33.7 ± 23.5
Free testosterone (pg/mL) 2.0 ± 1.5 2.6 ± 1.8
TSH (μIU/mL) 1.9 ± 1.2 1.9 ± 1.0
Thyroid antibodies 22.0% 16.0%
Anti-adrenal antibodies 0.3% 0%
Anti-ovarian antibodies 9.3% 6.4%
Antinuclear antibodies (ANA) 13.0% 7.2%
Antiphopholipid antibodies (APA) 14.6% 14.4%
Gammopathy 32.0% 36.0%
Immune system activation*** 59.0% 59.2%
*Values are presented as means ± standard deviation or as percentages.
Patient characteristics did not differ between both groups except for DHEAS
(P < 0.001), total testosterone (P < 0.001) and free testosterone (P < 0.01),
all three the consequence of DHEA supplementation for women with LFOR
between baseline evaluation and IVF cycle start. For further detail, see text.
Percentages among antibodies represent percentages of patients with positive
antibody tests.
**BMI, body mass index.
***Defined by presence of at least 1 positive laboratory test.
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preeclampsia/ eclampsia [8,9].
We recently noted that women with low functional
ovarian reserve (LFOR) at practically all ages are
characterized by relative hypoandrogenism [10]. Yet,
somewhat counter intuitively, we also discovered that
they demonstrated no evidence whatsoever of immune
system activation as we initially had hypothesized; yet,
young, healthy control patients with normal androgen
levels, to some degree did demonstrate evidence of
immune system activation [11].
Based on these unexpected findings, we further
hypothesized that normal androgen levels, in females
approximately equally adrenal and ovarian in origin,
depend on mild immune system activation. In absence of
activation by an immune system – driven androgen
production factor (APF), androgen levels decrease and
androgen-dependent early stages of follicle maturation
wither [2]. Under this hypothesis, the establishment
of pregnancy, thus, would be dependent on mild immune
system activation.
While this on first impression may sound like a coun-
ter intuitive proposition, various important stages of
reproduction, including ovulation and implantation, have
already been identified as “inflammatory” processes [12,13].
Here presented study was, therefore, designed to further
explore observable effects of immune system activation,
and how they may relate to reproductive success.
Methods
Institutional review board
Here presented study involved two distinct patient
populations, both of which were identified and retrieved
from our center’s electronic research data base, where
selected medical record data from presenting patients are
stored in anonymized fashion for research purposes. Prior
to inclusion in this research data bank, patients at our
center at initial presentation sign an informed consent,
which authorizes the use of their medical record data for
research purposes, as long as data remain confidential and
the identity of the patient remains protected. Both of
these conditions are met when data are extracted
from the center’s electronic research database, and the
study, therefore, underwent only expedited review and
approval from the center’s Institutional Review Board
(ER12172012-01, December 18, 2012).
Patient populations and main outcome measures
This study involved 2 patient populations: Group 1
included 322 consecutive infertile women, who presented
to our center for initial diagnostic evaluation at mean age
of 38.6 ± 5.4 years. Among those 125 women (Group 2)
underwent 169 IVF cycles, with some patients, thus,
undergoing more than one IVF cycle. Their mean age was38.9 ± 5.4 years. Table 1 summarizes patient characteristics
for both patient groups, and demonstrates that they in all
characteristics were very similar.
In order to qualify for Group 1, patients had to have a
complete initial data set of laboratory results in the
center’s electronic database, which, among immune
test, included antinuclear antibody, an antiphospholipid
antibody panel, including antibodies to β2-glycoprotein,
cardiolipin and phosphatidylserine in IgG, IgM and IgA
isotypes, a lupus anticoagulant, an antithyroid antibody
panel, including antibodies to thyroid peroxidase, thyro-
globulin and thyrotropin receptor, total IgG, IgM, IgA and
IgE levels, anti-adrenal antibodies (to 21-hydroxylase) and
anti-ovarian antibodies. All of these laboratory tests were
obtained via commercially available assays.
Because this panel of tests has in studies been proven
effective in discriminating with high sensitivity, though
relatively poor specificity, women with immune system
activation from those with a quiescent immune system,
it is part of our center’s routine initial fertility evaluation
at time of presentation. Fully expecting a high degree of
false-positivity, any positive finding in the panel is clinically
considered to represent immune system activation, and
only complete absence of any positive findings is clinically
considered a quiescent immune system [11].
In this context the expectation is to achieve high sensi-
tivity but poor specificity of diagnosis. This means that the
Table 2 Statistically significant associations
Associations Significance
TT/FT with presence of gammopathies (IgG, IgM, IgA, IgE) P = 0.026
Immune system activation* with embryo quality P = 0.008
After adjustments for age and repeat cycles P = 0.006
TT/FT, total/free testosterone ratio.
*As defined in Table 1.
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mated; yet, patients considered quiescent will, indeed, with
high certainty lack immune system hyperactivity. In this
context, statistical associations with immune system
activation will, therefore, be clinically diluted by the
presence of false positive patients and, therefore,
underestimated. So demonstrated statistically significant
associations, therefore, have to be considered statistically
sound.
Since women with LFOR demonstrate low androgen
levels [10], we now also routinely assess androgens in
newly presenting patients. Group 1 patients, therefore, also
had to have a completed set of androgen values in the cen-
ter’s research database, including dehydroepiandrosterone
(DHEA), DHEA-sulfate (DHEAS), free testosterone (FT)
and total testosterone (TT). All of above noted laboratory
tests were performed by routine commercial assays,
as previously reported, with TT being evaluated with
chromatography-tandem mass spectrometry [11].
We then assessed whether in Group 1 patients indi-
vidual immune parameters or whole immune panels
(i.e., thyroid antibodies, antiphospholipid antibodies,
total immunoglobulins, etc.) statistically correlated with
androgen levels.
As noted above, Group 2 patients, represented as sub-
set 125 infertile women (mean age 38.9 ± 5.4 years), hav-
ing undergone 169 IVF cycles within 2–4 weeks from
last laboratory assessments (Table 1). Group 2 patients
were used to assess whether immune parameters statisti-
cally correlated with embryo quality in IVF cycles.
Embryo quality was assessed in a total of 777 embryos.
Each embryo is individually evaluated under the
microscope early in the morning of day-3. Embryo
assessments are performed at our center by counting
blastomeres, assessing embryo shape, and determining
the degree of fragmentation. Embryos were graded
based on the following parameters: Excellent or Grade 5,
reached 8 cells with <5% fragmentation; Good or Grade 4,
reached 6–8 cells with ≤5% fragmentation; Average or
Grade 3, 6–8 cells with 5-20% fragmentation; Poor or
Grade 2, reached 4–8 cells with 20-40% fragmentation;
Very poor or Grade 1, 4–8 cells, with >40% fragmentation.
Statistical analyses
To investigate the effects androgen levels on immune
system activation, generalized linear mixed-effects models
(GLME) were used. GLME were also used to study the
effects of immune system activation on embryo quality.
The models were then controlled for age and repeated
cycles in Group 2. Analyses were conducted using SAS
9.2. P-values <0.05 were considered statistically significant.
All original data are available to investigators from CHR’s
electronic data depository by contacting David H. Barad,
MD, MS at dbarad@thechr.com.Results
Group-1 results
Patient characteristics for this group of infertility patients
are summarized in Table 1. As the table demonstrates,
their mean age was 38.6 ± 5.4 years. Their body mass
index (BMI) was 24.0 ± 4.9 kg/m2.
It is also important to note that except for DHEAS and
testosterone levels, none of the other patient characteristics
differed between Groups 1 and 2. DHEA and testosterone
levels increased in Group 2 patients because our center
routinely supplements women with LFOR prior to IVF
cycle start (see below).
Looking at the patients’ individual levels of DHEA,
DHEAS, TT, FT and TT/FT-ratios, none was indi-
vidually associated with laboratory evidence of thyroid
autoimmunity, presence of elevated antiphospholipid
antibodies, antinuclear antibodies, anti-adrenal auto-
immunity or anti-ovarian antibodies. TT/FT ratios were,
however, statistically associated with gammopathies, either
abnormally high or low total immunoglobulin levels in all
isotypes (P = 0.026; Table 2).
Group-2 results
Even more interesting, however, were observations in
Group 2, where the mean age was almost identical to
Group-1 patients (38.9 ± 5.4 years, Table 1). Out of 777
embryos, 353 (45.4%) were of good, 337 (43.4%) were of
fair and 87 (11.2%) were of poor quality. Defining immune
system activation as presence of one or more immune
abnormalities, evidence for female immune system activa-
tion was associated with significantly better embryo
quality than absence of such evidence (P = 0.008). This
association, indeed, persisted even after adjustments for
female age and repeat IVF cycles (P = 0.006), strongly sug-
gesting that mild immune system activation offers benefits
in regard to embryo quality. The observed improvement
in embryo quality was primarily the consequence of
higher embryo grades (3.7 ± 0.05 vs. 3.4 ± 0.07; P = 0.002).
Discussion
Here presented data on random female infertility patients
confirm the previously reported association between
androgen levels and immune system activation [11], this
time, however, even more specifically demonstrating
that abnormalities in total immunoglobulin levels are
statistically associated with TT/FT ratios.
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TT/FT ratios are to a large degree dependent on sex
hormone binding globulin (SHBG), as defined by the Free
Androgen Index FAI ¼ 100  TTSHBG
 
[14]. While we,
unfortunately, in this study did not have data on SHBG,
these observations potentially link immunoglobulin
concentrations via androgen levels to SHBG levels, as
androgens are known to decrease SHBG [15,16], thus
resulting in more of bioactive FT becoming available.
The association of TT/FT ratios and immunoglobulin
abnormalities supports the previously reported association
between mild immune system activation [11], normal
ovarian function and normal androgen levels; while
women with abnormally low ovarian function not only
lack evidence of immune system activation but also
demonstrate comparatively low androgen levels [10].
We, therefore, hypothesized about existence of a poten-
tial “immunologic” androgen production factor (APF),
responsible for maintaining appropriate androgen levels
for normal female fertility, which may be potentially
increased in association with polycystic ovarian syndrome
(PCOS) and decreased in women with LFOR ([11] and
reviewed in [2]). Here presented data offer further support
for such a hypothetical APF.
A possible association between immune system activation
and embryo quality has never before ben reported. This
observations in Group 2-women is, therefore, likely even
more significant. It is not only statistically very robust but
even held up after adjustment for age and number of earlier
IVF cycles, suggesting that it is independent of female
age and, at least to a degree, independent of severity
of infertility.
Combined, these observations, therefore, suggest that
a mild form of immune system activation may represent a
highly important theme throughout all stages of successful
reproduction, starting with egg/embryo quality, as here
reported for the first time.
This concept is not necessarily new: For example,
Jabbour et al. pointed out the importance of inflammatory
pathways throughout reproductive physiology, from ovu-
lation, to menstruation, implantation and onset of labor,
all now increasingly perceived as inflammatory processes
[17]. Here presented study suggests that creation of good
embryo quality now also may have to be added as a
process dependent on inflammatory pathways.
All of these observations also explain the close relation-
ship and interplay between endocrine and immune systems,
recently increasingly addressed in the literature [2,9].
How an activated immune system could beneficially
affect egg and embryo quality remains to be established.
Androgens, however, allow for a hypothesis: Recently
reported animal models [18,19] and human clinical
data ([20] reviewed in [21]), suggest that androgens are
essential for early stages of follicle maturation. Improvingegg/embryo quality via androgen supplementation in
women with LFOR and with low androgen levels,
therefore, appears to increase pregnancy chances [20],
to reduce aneuploidy in embryos [22] and, therefore,
miscarriage rates [23].
Androgens are, however, also strongly anti-inflammatory,
and are, therefore, for that purpose clinically, for example,
utilized in autoimmune disease [24]. The previously noted
hypothetic immune system-derived APF with the ability to
increases androgen levels, thus, potentially can create a
feed-back loop by inducing anti-inflammatory androgens
which, in turn, keep a low-level of inflammatory immune
system activation in check.
In conclusion, here presented results add to an increasing
volume of data pointing toward significant interaction
between endocrine and immune systems in establishing
reproductive success. Albertini recently described the
ovaries as immunological “hot-spots” [25] based on the
recognition that increasing numbers of fertility-associated
genes in the ovary also have immunological functions. It
increasingly appears that other endocrine organs may
deserve a similar designation. Indeed, the brain and other
endocrine organs like the adrenals, increasingly appear
to represent locations where endocrine and immune
systems almost merge into one immune/endocrine
system (2). For successful reproduction the flawless func-
tion of this united system appears increasingly essential.
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